Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSL | P07711 | 14/20 | 0.53 |
| ▸ | CTSB | P07858 | 14/20 | 0.53 |
| ▸ | CTSS | P25774 | 13/20 | 0.53 |
| ▸ | CTSK | P43235 | 12/20 | 0.53 |
| ▸ | CTSV | O60911 | 5/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6208306 | 1.00 | CTSL (0.53) | CTSLCTSBCTSSCTSKCTSV | |
| SCHEMBL6268990 | 0.96 | CTSK (0.49) | CTSLCTSBCTSSCTSKCTSV | |
| SCHEMBL6268987 | 0.96 | CTSK (0.49) | CTSLCTSBCTSSCTSKCTSV | |
| SCHEMBL6189091 | 0.95 | CTSK (0.48) | CTSLCTSBCTSSCTSKCTSV | |
| SCHEMBL6189086 | 0.95 | CTSK (0.48) | CTSLCTSBCTSSCTSKCTSV | |
| SCHEMBL6266806 | 0.92 | CTSL (0.50) | CTSLCTSBCTSSCTSKCTSV | |
| SCHEMBL6266810 | 0.92 | CTSL (0.50) | CTSLCTSBCTSSCTSKCTSV | |
| SCHEMBL6265766 | 0.90 | CTSL (0.52) | CTSLCTSBCTSSCTSKCTSV | |
| SCHEMBL6265763 | 0.90 | CTSL (0.52) | CTSLCTSBCTSSCTSKCTSV | |
| SCHEMBL5801033 | 0.88 | CTSK (0.49) | CTSLCTSBCTSSCTSKCTSV |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2005097103-A2 | DIABETES AND METABOLIC SYNDROME THERAPY UTILIZING CATHEPSIN B INHIBITORS | AXYS PHARMACEUTICALS, INC. (US) | 2005-10-20 | — | — | WO | claimed |
| US-20050282871-A1 | 3-(3,5-Disubstituted-4-hydroxyphenyl)propionamide derivatives as cathepsin b inhibitors | BURRILL II LELAND C | 2005-12-22 | — | — | US | disclosed |
| WO-2005097103-A2 | DIABETES AND METABOLIC SYNDROME THERAPY UTILIZING CATHEPSIN B INHIBITORS | AXYS PHARMACEUTICALS, INC. (US) | 2005-10-20 | — | — | WO | disclosed |
| EP-1539725-A1 | 3-(3,5-DISUBSTITUTED-4-HYDROXYPHENYL)PROPIONAMIDE DERIVATIVES AS CATHEPSIN B INHIBITORS | AXYS PHARMACEUTICALS, INC. (US) | 2005-06-15 | — | — | EP | disclosed |
| WO-2004026851-A1 | 3-(3,5-DISUBSTITUTED-4-HYDROXYPHENYL)PROPIONAMIDE DERIVATIVES AS CATHEPSIN B INHIBITORS | AXYS PHARMACEUTICALS, INC. (US) | 2004-04-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050282871-A1 | 3-(3,5-Disubstituted-4-hydroxyphenyl)propionamide derivatives as cathepsin b inhibitors | CTSB, CTSZ, CTSS | CTSL 14/4885CTSB 1/4885CTSS 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.